Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Shorting
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Comment by Superss63on Apr 29, 2021 3:51pm
268 Views
Post# 33095292

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Shorting

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Shorting
TeddyTenBags wrote: Nope. Was 18% yesterday and that's just short volume as a % of total volume. The total amount of shorts vs. the total share count is miniscule. Nice try though.

Superss63 wrote:

 

TeddyTenBags wrote: Courage? How about putting your money where your mouth is. Sounds like we've got a pumping bagholder who's upset that he bought at $7.

Less than 1% of the total share count is shorted. 

 

 

Yeah, okay,     

% of Vol Shorted
Apr 28 33.57
 





Historical Short Volume Data for MMEDF
Date Close High Low Volume Short Volume % of Vol Shorted
Apr 26 NA NA NA 21,871,617 13,345,728 61.02
Apr 23 NA NA NA 14,722,292 8,807,120 59.82
Apr 22 NA NA NA 1,013,057 444,502 43.88
Apr 21 NA NA NA 1,427,915 469,983 32.91
Apr 20 NA NA NA 2,385,139 720,049 30.19
Apr 19 NA NA NA 1,560,065 507,339 32.52
Apr 16 NA NA NA 1,124,960 372,930 33.15
Apr 15 NA NA NA 860,595 266,104 30.92
Apr 14 NA NA NA 1,273,107 375,304 29.48
Apr 13 NA NA NA 823,840 300,320 36.45
Apr 12 NA NA NA 624,347 227,189 36.39
Apr 09 NA NA NA 659,822 329,967 50.01
Apr 08 NA NA NA 963,436 406,796 42.22
Apr 07 NA NA NA 911,595 346,952 38.06
Apr 06 NA NA NA 1,173,587 492,852 42.00
Apr 05 NA NA NA 1,225,716 466,873 38.09
Apr 01 NA NA NA 2,753,130 1,342,231 48.75
Mar 30 NA NA NA 2,134,647 881,174 41.28




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities